Kamada Ltd.
KMDA Healthcare Drug Manufacturers Specialty & Generic
Kamada Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $180.5 million, up 12.1% from fiscal 2024. In the quarter to June 2026, revenue grew 22.7%, EPS grew 23.1%, free cash flow grew 165.7% and total debt fell 38.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow KMDA
Kamada Ltd. (KMDA) P/E ratio
As of 16 October 2026, Kamada Ltd. (KMDA) trades at a P/E ratio of 20.4×. Over the past ten years it has ranged from 0.0× (June 2023) to 72.9× (August 2023); the current reading is higher than 72% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 19.2× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 20.2× | (13.88%) |
| FY2024 | 23.4× | (39.16%) |
| FY2023 | 38.5× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 16.6× | 31.37% |
| FY2019 | 12.6× | 39.13% |
| FY2018 | 9.1× | (67.80%) |
| FY2017 | 28.2× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 19.3× | (18.94%) |
| Mar 2026 | 23.8× | 18.13% |
| Dec 2025 | 20.2× | 4.64% |
| Sep 2025 | 19.3× | (15.43%) |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| EBS Emergent Biosolutions Inc. compare | n/m |
| TKNO Alpha Teknova, Inc. compare | n/m |
| AQST Aquestive Therapeutics, Inc. compare | n/m |
| EVO Evotec AG compare | n/m |
| TLRY Tilray Brands, Inc. compare | n/m |
| EOLS Evolus, Inc. compare | n/m |
| CGC Canopy Growth Corporation compare | n/m |
| IRWD Ironwood Pharmaceuticals, Inc. compare | 4.4× |
| KMDA Kamada Ltd. | 20.4× |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)